Skip to main content

Table 2 Rating scale assessments

From: Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

Rating scale

[ … ]

UPDRS Part II (ADL during OFF); mean ± SD

 Baseline (n = 475)

17.1 ± 7.0

 3 months (n = 389)

13.9 ± 6.8

 Change from baseline (n = 389)

− 3.0 ± 4.6

P value vs. baseline

< 0.0001

UPDRS Part III (motor scores during ON); mean ± SD

 Baseline (n = 476)

26.5 ± 12.1

 3 months (n = 391)

21.5 ± 11.0

 Change from baseline (n = 391)

− 4.6 ± 8.1

P value vs. baseline

< 0.0001

[…]

  1. NMSS Non-motor symptom scale, UPDRS Unified Parkinson’s Disease Rating Scale, PDQ-8 Parkinson’s Disease Questionnaire